Clinical trials
Unresectable Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting unresectable hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 137 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07175441RecruitingPhase 2
Testing a new drug combo for advanced liver cancer
This trial tests a new drug called RBS2418 added to two immunotherapy medicines (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination helps patients who are starting their first treatment for this stage of liver cancer.
Baltimore, MarylandAges 18 years+ - NCT07141056Recruiting
Emotional stress and immunotherapy for liver cancer
This study looks at how emotional stress affects how well immunotherapy works for liver cancer. It is for people with liver cancer who are about to start immunotherapy, either before or after surgery, or as first treatment for advanced cancer.
Zhanjiang, GuangdongAges 18 years+ - NCT07099274RecruitingPhase 2
Combination treatment for advanced liver cancer
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07100392RecruitingPhase 2
A new drug combo for advanced liver cancer after first treatment fails
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06911255RecruitingPhase 1/Phase 2
Testing two immunotherapy drugs with chemoembolization for liver cancer
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
SeoulAges 19 years+ - NCT06741020RecruitingPhase 1/Phase 2
Chemo and Immunotherapy before Liver Cancer Surgery
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Hangzhou, ZhejiangAges 18–75 - NCT07047586RecruitingPhase 2
Lenvatinib plus Tislelizumab vs Lenvatinib alone for liver cancer
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07010497RecruitingPhase 2
Study of a three-drug combo for advanced liver cancer
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
SeoulAges 19 years+ - NCT07001085Recruiting
Blood test to monitor liver cancer after surgery
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Warsaw, Masovian VoivodeshipAges 18–75 - NCT06921785RecruitingPhase 3
Combination therapy for first-line liver cancer treatment
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
Phoenix, ArizonaAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other tumors with specific genetic changes
This trial tests a new pill, TYRA-430, for people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have certain genetic changes (in the FGF/FGFR pathways). It aims to see if the drug is safe and if it can shrink or slow the growth of the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06880523RecruitingPhase 2
Adding lenvatinib to immunotherapy for liver cancer
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
Calgary, AlbertaAges 18 years+ - NCT06882876Enrolling by invitationPhase 1
Study of JS014, Toripalimab and TACE for Untreated Liver Cancer
This trial combines an investigational drug (JS014) with a standard immunotherapy (Toripalimab) and a procedure called TACE (tiny beads placed into the liver's blood vessels to block tumor feeding) for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors or slow their growth.
Changsha, HunanAges 18–75 - NCT06852820RecruitingPhase 2
PSMA-targeted radioactive therapy for advanced liver cancer
This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.
Cleveland, OhioAges 18 years+ - NCT06828380RecruitingPhase 2
Immunotherapy with or without radiation for liver cancer
This trial tests whether using immunotherapy alone works as well as immunotherapy combined with radiation for liver cancer that has spread into major blood vessels. The goal is to find the best treatment option for people with this specific type of advanced liver cancer.
GoyangAges 19 years+ - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06789757RecruitingPhase 2
Study of 3 drugs for liver cancer that can't be removed by surgery
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
Fairfax, VirginiaAges 18 years+ - NCT06737913RecruitingPhase 2
Study of adebrelimab and bevacizumab with liver chemo for advanced liver cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
Lanzhou, GansuAges 18 years+ - NCT06726161RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced liver cancer
This trial tests a new way to find and treat liver cancer that cannot be removed by surgery. First, a special dye (RYZ811) is used to see if your cancer cells have a marker called GPC3. If they do, you may receive a targeted radiation treatment (RYZ801) that seeks out those cells. This trial is for people whose liver cancer has grown despite receiving at least one prior therapy.
Birmingham, AlabamaAges 18 years+ - NCT06551272RecruitingPhase 2
Gut bacteria change to help immunotherapy for liver cancer
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
BobignyAges 18 years+ - NCT06280313Recruiting
Splenectomy with targeted therapy and immunotherapy for liver cancer
This trial tests whether removing the spleen (splenectomy) can improve the effectiveness of targeted therapy and immunotherapy for people with advanced liver cancer (HCC) who also have enlarged spleens due to portal hypertension. It aims to see if this combination can help control the cancer better.
Wuhan, HubeiAges 18–75 - NCT06600321RecruitingPhase 1
Study of ALN-BCAT for liver cancer
This trial tests a new drug called ALN-BCAT for people with advanced liver cancer (hepatocellular carcinoma) that has a specific genetic change. If you have already tried at least one treatment, this study may be an option for you.
Phoenix, ArizonaAges 18 years+
Hear when a new Unresectable Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 137 recruiting unresectable hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.